Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma

Cancer,

The current analysis provided additional level 2 evidence supporting the use of concurrent rituximab plus infusional etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R–EPOCH) in patients with human immunodeficiency virus (HIV)–associated lymphoma and a CD4 count >50/µL, and the results support the design of an ongoing phase 3 trial comparing concurrent R–EPOCH with R–CHOP in immunocompetent patients with diffuse large B–cell lymphoma .

Print Article Summary Cat 2 CME Report